| Previous Close | 3.07 |
| Open | 3.1 |
| Day High | 3.25 |
| Day Low | 3.1 |
| 52-Week High | 55.6 |
| 52-Week Low | 3.06 |
| Volume | 63,389 |
| Average Volume | 206,003 |
| Market Cap | 2.31M |
| PE | -0.05 |
| EPS | -68.4 |
| Moving Average 50 Days | 5.73 |
| Moving Average 200 Days | 13.82 |
| Change | 0.13 |
Beyond Air to Participate in the 38th Annual Roth Conference in March
GlobeNewswire Inc.
Mar 11, 2026 11:00 AM GMT
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
GlobeNewswire Inc.
Mar 10, 2026 11:30 AM GMT
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th